Cargando…

Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States

INTRODUCTION: Thyroid eye disease (TED) is an autoimmune condition producing ocular pain, dysmotility, and ocular structure and function changes. As disease activity changes, redness, swelling, and pain can improve, but eye comfort, appearance, and motility alterations often persist. There are limit...

Descripción completa

Detalles Bibliográficos
Autores principales: Cockerham, Kimberly P., Padnick-Silver, Lissa, Stuertz, Noel, Francis-Sedlak, Megan, Holt, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589903/
https://www.ncbi.nlm.nih.gov/pubmed/34478126
http://dx.doi.org/10.1007/s40123-021-00385-8
_version_ 1784598832181411840
author Cockerham, Kimberly P.
Padnick-Silver, Lissa
Stuertz, Noel
Francis-Sedlak, Megan
Holt, Robert J.
author_facet Cockerham, Kimberly P.
Padnick-Silver, Lissa
Stuertz, Noel
Francis-Sedlak, Megan
Holt, Robert J.
author_sort Cockerham, Kimberly P.
collection PubMed
description INTRODUCTION: Thyroid eye disease (TED) is an autoimmune condition producing ocular pain, dysmotility, and ocular structure and function changes. As disease activity changes, redness, swelling, and pain can improve, but eye comfort, appearance, and motility alterations often persist. There are limited data on chronic TED patient-reported outcomes. This study examined chronic US TED patient-reported symptoms and quality of life (QOL). METHODS: Existing data from an online survey regarding chronic TED signs/symptoms and patient QOL were retrospectively examined. The Graves’ Ophthalmopathy QOL instrument (GO-QOL; 0–100, 100 = highest QOL) evaluated overall, appearance, and vision-related QOL. Influencing factors were examined by stratifying patients into low (overall QOL ≤ 50), moderate (> 50 and < 75), and high (≥ 75) QOL categories. RESULTS: One hundred patients (47 women, 81 Caucasian, 45.2 ± 7.6 years) were included. The duration of inactive TED was 3.0 ± 4.6 years and total duration of TED was 5.8 ± 5.9 years. Patients reported an average of 20 doctor visits/year and high prevalence of anxiety (34%) and depression (28%). Prior TED treatments for the polled population included systemic corticosteroids during active TED (25%), orbital radiation (5%), and surgery (25%). The overall GO-QOL score was 60.5 ± 21.8 (vision-related: 58.6 ± 24.0, appearance-related: 62.3 ± 25.1). Patients with low QOL more frequently reported hypothyroidism, anxiety, and a larger number of chronic TED signs/symptoms (average: 4.2). Compared to high QOL patients, low QOL patients had more pain (39% vs. 13%), blurry vision (30% vs. 17%), and diplopia (27% vs. 3%, all p ≤ 0.025). Additionally, the low QOL group more often had TED-specific surgical history (45% vs. 10%, p = 0.002), more often reported disability/unemployment (21% vs. 3%, p = 0.055), and had a higher number of doctor visits (40 vs. 5 visits/person/year, p < 0.001). CONCLUSION: TED severely impacts patient QOL, despite becoming stable and chronic. Patients reported vision and appearance impairment and psychosocial impact long after acute TED had subsided. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40123-021-00385-8.
format Online
Article
Text
id pubmed-8589903
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-85899032021-11-23 Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States Cockerham, Kimberly P. Padnick-Silver, Lissa Stuertz, Noel Francis-Sedlak, Megan Holt, Robert J. Ophthalmol Ther Original Research INTRODUCTION: Thyroid eye disease (TED) is an autoimmune condition producing ocular pain, dysmotility, and ocular structure and function changes. As disease activity changes, redness, swelling, and pain can improve, but eye comfort, appearance, and motility alterations often persist. There are limited data on chronic TED patient-reported outcomes. This study examined chronic US TED patient-reported symptoms and quality of life (QOL). METHODS: Existing data from an online survey regarding chronic TED signs/symptoms and patient QOL were retrospectively examined. The Graves’ Ophthalmopathy QOL instrument (GO-QOL; 0–100, 100 = highest QOL) evaluated overall, appearance, and vision-related QOL. Influencing factors were examined by stratifying patients into low (overall QOL ≤ 50), moderate (> 50 and < 75), and high (≥ 75) QOL categories. RESULTS: One hundred patients (47 women, 81 Caucasian, 45.2 ± 7.6 years) were included. The duration of inactive TED was 3.0 ± 4.6 years and total duration of TED was 5.8 ± 5.9 years. Patients reported an average of 20 doctor visits/year and high prevalence of anxiety (34%) and depression (28%). Prior TED treatments for the polled population included systemic corticosteroids during active TED (25%), orbital radiation (5%), and surgery (25%). The overall GO-QOL score was 60.5 ± 21.8 (vision-related: 58.6 ± 24.0, appearance-related: 62.3 ± 25.1). Patients with low QOL more frequently reported hypothyroidism, anxiety, and a larger number of chronic TED signs/symptoms (average: 4.2). Compared to high QOL patients, low QOL patients had more pain (39% vs. 13%), blurry vision (30% vs. 17%), and diplopia (27% vs. 3%, all p ≤ 0.025). Additionally, the low QOL group more often had TED-specific surgical history (45% vs. 10%, p = 0.002), more often reported disability/unemployment (21% vs. 3%, p = 0.055), and had a higher number of doctor visits (40 vs. 5 visits/person/year, p < 0.001). CONCLUSION: TED severely impacts patient QOL, despite becoming stable and chronic. Patients reported vision and appearance impairment and psychosocial impact long after acute TED had subsided. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40123-021-00385-8. Springer Healthcare 2021-09-03 2021-12 /pmc/articles/PMC8589903/ /pubmed/34478126 http://dx.doi.org/10.1007/s40123-021-00385-8 Text en © The Author(s) 2021, corrected publication 2022 https://creativecommons.org/licenses/by-nc/4.0/Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Cockerham, Kimberly P.
Padnick-Silver, Lissa
Stuertz, Noel
Francis-Sedlak, Megan
Holt, Robert J.
Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States
title Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States
title_full Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States
title_fullStr Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States
title_full_unstemmed Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States
title_short Quality of Life in Patients with Chronic Thyroid Eye Disease in the United States
title_sort quality of life in patients with chronic thyroid eye disease in the united states
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589903/
https://www.ncbi.nlm.nih.gov/pubmed/34478126
http://dx.doi.org/10.1007/s40123-021-00385-8
work_keys_str_mv AT cockerhamkimberlyp qualityoflifeinpatientswithchronicthyroideyediseaseintheunitedstates
AT padnicksilverlissa qualityoflifeinpatientswithchronicthyroideyediseaseintheunitedstates
AT stuertznoel qualityoflifeinpatientswithchronicthyroideyediseaseintheunitedstates
AT francissedlakmegan qualityoflifeinpatientswithchronicthyroideyediseaseintheunitedstates
AT holtrobertj qualityoflifeinpatientswithchronicthyroideyediseaseintheunitedstates